Seon-Young Park

Seon-Young Park


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
DSDhiraj kumar sah
Dhiraj kumar sah
AAArchana Arjunan
Archana Arjunan
SPSeon-Young Park
Seon-Young Park
BLBora Lee
Bora Lee
Young Do JungYoung Do Jung
Young Do Jung
Colorectal cancer (CRC) stands as a major cause of cancer-related mortality globally, accounting for approximately 881,000 deaths each year. Traditional approaches such as chemotherapy and surgery have been the primary treatment modalities, yet the outcomes for patients with metastatic CRC are often unsatisfactory. Recent research has focused on targeting the pathways involved in oxidative stress, inflammation, and metastasis to enhance the survival of CRC patients. Within this context, sulforaphane (SFN), a notable phytochemical found predominantly in cruciferous vegetables, has been recognized as a potential anticancer agent. However, the specific mechanisms through which SFN may exert its chemopreventive effects in CRC remain unclear. This study explores the impact of SFN on IL-1β-induced IL-6 activation and MAPK and AP-1 signaling in HT-29 cells. Our findings reveal that SFN treatment not only diminishes IL-1β-stimulated IL-6 expression but also reduces oxidative stress by curtailing reactive oxygen species (ROS) production. Furthermore, it hinders the proliferation and invasiveness of HT-29 cells through the modulation of MAPK/AP-1 and STAT3 signaling pathways. These results indicate that SFN mitigates IL-1β-induced IL-6 expression in CRC cells by attenuating ROS production and disrupting MAPK/AP-1 signaling. This suggests that SFN holds significant potential as a chemotherapeutic agent for both treating and preventing CRC.

5 August 2016 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
SPSeon-Young Park
Seon-Young Park
JKJi-Young Kim
Ji-Young Kim
SLSu-Mi Lee
Su-Mi Lee
JCJin Ook Chung
Jin Ook Chung
KLKyung-Hwa Lee
Kyung-Hwa Lee
YLYong Han Lee
Yong Han Lee
Several studies have demonstrated a correlation between the expression of early growth response gene‑1 (EGR‑1) and the progression of gastric cancers at advanced stages. However, the effects of EGR‑1 expression on human gastric cancer progression, particularly on precancerous lesions, have not been investigated. In this study, we evaluate EGR‑1 expression levels in target mucosa from patients with early gastric cancer and precancerous lesions, and assess whether EGR‑1 expression affects the oncogenic phenotypes of human gastric cancer cells. EGR‑1 protein levels were measured in tissues from subjects with normal mucosa (n=6), low‑grade dysplasia (n=6), high‑grade dysplasia (n=4) and adenocarcinoma (n=3) using enzyme‑linked immunosorbent assay and immunohistochemistry analyses. We also investigated the role of EGR‑1 in tumor cell behavior by transiently expressing a dominant active EGR‑1 variant in cultured cells. A positive correlation was observed between EGR‑1 expression and gastric carcinogenesis (P=0.016). Furthermore, there was an increase in nuclear and cytoplasmic expression of EGR‑1 in accordance with the histological grade (P for trends=0.003 and 0.003, respectively), and a positive association between the sum of the nuclear and cytoplasmic EGR‑1 expression values and the histological grade (P=0.003). In addition, transient over­expression of EGR‑1 enhanced cell proliferation, stimulated cell migration, and promoted the phosphorylation of p38 MAPK and AKT in gastric cancer cells in vitro. Our findings demonstrate that EGR‑1 may contribute to the early stages of gastric carcinogenesis via the alteration of tumor cell behaviors.